<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03996239</url>
  </required_header>
  <id_info>
    <org_study_id>19-126</org_study_id>
    <nct_id>NCT03996239</nct_id>
  </id_info>
  <brief_title>Researching the Effect of Aerobic Exercise on Cancer</brief_title>
  <official_title>Exercise as Interception Therapy: A &quot;Proof-of-Concept&quot; Digitized Trail</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Memorial Sloan Kettering Cancer Center</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Memorial Sloan Kettering Cancer Center</source>
  <oversight_info>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      This study is being done to answer the following question: Will aerobic exercise (exercise&#xD;
      that stimulates and strengthens the heart and lungs, and improves the body's use of oxygen)&#xD;
      change the biomarkers (signs of disease) found in the blood?&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">June 20, 2019</start_date>
  <completion_date type="Anticipated">June 2022</completion_date>
  <primary_completion_date type="Anticipated">June 2022</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Non-Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Double (Participant, Investigator)</masking>
    <masking_description>For cohort 3 only. Men with histologically-confirmed localized prostate cancer undergoing active surveillance. Both patients and investigators will be fully blinded to the ctDNA status of patients during study participation.</masking_description>
  </study_design_info>
  <primary_outcome>
    <measure>number of patients with variant allele frequency (VAF)</measure>
    <time_frame>2 years</time_frame>
    <description>measured by targeted CH panel in peripheral blood</description>
  </primary_outcome>
  <primary_outcome>
    <measure>changes in residual tumor burden (Solid tumor group)</measure>
    <time_frame>2 years</time_frame>
    <description>measured by the amount of circulating tumor DNA (ctDNA)</description>
  </primary_outcome>
  <number_of_arms>3</number_of_arms>
  <enrollment type="Anticipated">48</enrollment>
  <condition>Cancer</condition>
  <arm_group>
    <arm_group_label>patients with clonal hematopoiesis</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Exercise treatment will consist of individualized walking delivered up to 5 times weekly. Patients in all cohorts will receive one dose of exercise (i.e., ~300 mins/wk following a non-linear dosing schedule) in both cohorts. Patients will have the option to receive exercise treatment at MSK or at their residence. Home-based exercise will be implemented and monitored using a telemedicine approach (i.e.,TeleEx) established in the Exercise-Oncology (ExOnc) Service</description>
  </arm_group>
  <arm_group>
    <arm_group_label>post treatment patients with breast or colorectal cancer</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Exercise treatment will consist of individualized walking delivered up to 5 times weekly. Patients in all cohorts will receive one dose of exercise (i.e., ~300 mins/wk following a non-linear dosing schedule) in both cohorts. Patients will have the option to receive exercise treatment at MSK or at their residence. Home-based exercise will be implemented and monitored using a telemedicine approach (i.e.,TeleEx) established in the Exercise-Oncology (ExOnc) Service</description>
  </arm_group>
  <arm_group>
    <arm_group_label>men with localized prostate cancer undergoing active surveillance</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Exercise treatment will consist of individualized walking delivered up to 5 times weekly. Patients in all cohorts will receive one dose of exercise (i.e., ~300 mins/wk following a non-linear dosing schedule) in both cohorts. Patients will have the option to receive exercise treatment at MSK or at their residence. Home-based exercise will be implemented and monitored using a telemedicine approach (i.e.,TeleEx) established in the Exercise-Oncology (ExOnc) Service</description>
  </arm_group>
  <intervention>
    <intervention_type>Behavioral</intervention_type>
    <intervention_name>exercise (walking)</intervention_name>
    <description>Exercise treatment will consist of individualized walking delivered up to 5 times weekly. This trial will evaluate one dose of exercise (i.e., ~300 mins/wk following a non-linear dosing schedule) in both cohorts. Patients will have the option to receive exercise treatment at MSK or at their residence. Home-based exercise will be implemented and monitored using a telemedicine approach (i.e.,TeleEx) established in the Exercise-Oncology (ExOnc) Service</description>
    <arm_group_label>men with localized prostate cancer undergoing active surveillance</arm_group_label>
    <arm_group_label>patients with clonal hematopoiesis</arm_group_label>
    <arm_group_label>post treatment patients with breast or colorectal cancer</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>plasma samples</intervention_name>
    <description>Plasma samples will be obtained at baseline.</description>
    <arm_group_label>men with localized prostate cancer undergoing active surveillance</arm_group_label>
    <arm_group_label>post treatment patients with breast or colorectal cancer</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>blood draw</intervention_name>
    <description>fasting blood</description>
    <arm_group_label>men with localized prostate cancer undergoing active surveillance</arm_group_label>
    <arm_group_label>patients with clonal hematopoiesis</arm_group_label>
    <arm_group_label>post treatment patients with breast or colorectal cancer</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
        Cohort 1: CH&#xD;
&#xD;
          -  CH called by MSK practices as documented by an MSK physician&#xD;
&#xD;
          -  Age ≥18 yrs&#xD;
&#xD;
          -  Completion of all anticancer therapy&#xD;
&#xD;
          -  High risk of cardiovascular disease defined by presence of at least one of the&#xD;
             following:&#xD;
&#xD;
               -  Age ≥60&#xD;
&#xD;
               -  Prior treatment with chemotherapy&#xD;
&#xD;
               -  Prior left-sided breast and/or chest wall radiotherapy&#xD;
&#xD;
               -  Currently receiving or previously received androgen deprivation therapy Prior&#xD;
                  bone marrow transplant&#xD;
&#xD;
               -  History of smoking&#xD;
&#xD;
               -  Currently treated for one or more cardiovascular risk factors (i.e.,&#xD;
                  hypertension, diabetes, hyperlipidemia)&#xD;
&#xD;
          -  Performing less than 150 minutes of structured moderate-intensity or&#xD;
             strenuous-intensity exercise per week, as evaluated by self-report&#xD;
&#xD;
          -  Willingness to comply with all study-related procedures&#xD;
&#xD;
        Cohort 2: Solid Tumor&#xD;
&#xD;
          -  Patients at risk of harboring circulating tumor DNA as defined by one of the&#xD;
             following:&#xD;
&#xD;
               -  Histologically confirmed stage III (i.e., high risk of recurrence) colorectal&#xD;
                  cancer within 2 years of completion of all adjuvant therapy.&#xD;
&#xD;
               -  Histologically confirmed stage III breast cancer with residual disease after&#xD;
                  neoadjuvant therapy and within 12 months of completing (neo)adjuvant chemotherapy&#xD;
&#xD;
               -  Patients with metastatic breast cancer and radiographic stable disease or NED for&#xD;
                  ≥6 months and not currently receiving chemotherapy (endocrine therapy and&#xD;
                  anti-HER2 antibodies allowed)&#xD;
&#xD;
          -  Age ≥ 18 yrs&#xD;
&#xD;
          -  Performing less than 150 minutes of structured moderate-intensity or&#xD;
             strenuous-intensity exercise per week, as evaluated by self-report&#xD;
&#xD;
          -  Willingness to comply with all study-related procedures&#xD;
&#xD;
        Cohort 3: Active Surveillance&#xD;
&#xD;
          -  Men with histologically confirmed localized prostate cancer undergoing active&#xD;
             surveillance&#xD;
&#xD;
          -  Age ≥ 18 yrs&#xD;
&#xD;
          -  Performing less than 30 minutes of structured moderate-intensity or&#xD;
             strenuous-intensity exercise per week, as evaluated by self-report&#xD;
&#xD;
          -  Willingness to comply with all study-related procedures&#xD;
&#xD;
          -  Cleared for exercise participation as per screening clearance via PAR-Q+&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Concurrent use of any form of antitumor therapy (endocrine therapy and anti-HER2&#xD;
             antibodies allowed)&#xD;
&#xD;
          -  Enrollment onto any other interventional investigational study&#xD;
&#xD;
          -  Any other current diagnosis of invasive cancer or hematologic cancer of any kind&#xD;
&#xD;
          -  Any other condition or intercurrent illness that, in the opinion of the investigator,&#xD;
             makes the subject a poor candidate for study participation.&#xD;
&#xD;
          -  Mental impairment leading to inability to cooperate&#xD;
&#xD;
          -  Any of the following contraindications to cardiopulmonary exercise testing (Cohorts 1&#xD;
             and 2 only):&#xD;
&#xD;
               1. Acute myocardial infarction within 3-5 days of any planned study procedures;&#xD;
&#xD;
               2. Unstable angina&#xD;
&#xD;
               3. Uncontrolled arrhythmia causing symptoms or hemodynamic compromise&#xD;
&#xD;
               4. Recurrent syncope&#xD;
&#xD;
               5. Active endocarditis&#xD;
&#xD;
               6. Acute myocarditis or pericarditis&#xD;
&#xD;
               7. Symptomatic severe aortic stenosis&#xD;
&#xD;
               8. Uncontrolled heart failure&#xD;
&#xD;
               9. Acute pulmonary embolus or pulmonary infarction within 3 months of any planned&#xD;
                  study procedures&#xD;
&#xD;
              10. Thrombosis of lower extremities within 3 months of any planned study procedures&#xD;
&#xD;
              11. Suspected dissecting aneurysm&#xD;
&#xD;
              12. Uncontrolled asthma&#xD;
&#xD;
              13. Pulmonary edema&#xD;
&#xD;
              14. Respiratory failure&#xD;
&#xD;
              15. Acute non-cardiopulmonary disorders that may affect exercise performance&#xD;
&#xD;
          -  Room air desaturation at rest ≤ 85% (Cohorts 1 and 2 only)&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Lee Jones, PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Memorial Sloan Kettering Cancer Center</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Lee Jones, PhD</last_name>
    <phone>646 888-8103</phone>
    <email>jonesl3@mskcc.org</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Jessica Scott, PhD</last_name>
    <phone>646 888-8103</phone>
    <email>scottj1@mskcc.org</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>University of California, Los Angeles (Data or Specimen Analysis Only)</name>
      <address>
        <city>Los Angeles</city>
        <state>California</state>
        <zip>90095</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Paul C Boutros, PhD</last_name>
      <phone>310-794-7160</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>SOMALOGIC (Data or Specimen Analysis Only)</name>
      <address>
        <city>Boulder</city>
        <state>Colorado</state>
        <zip>80301</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Paul Boutros, PhD</last_name>
      <phone>303-625-9000</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>Memoral Sloan Kettering Monmouth</name>
      <address>
        <city>Middletown</city>
        <state>New Jersey</state>
        <zip>07748</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Lee Jones, PhD</last_name>
      <phone>646-888-8103</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>Memorial Sloan Kettering Bergen</name>
      <address>
        <city>Montvale</city>
        <state>New Jersey</state>
        <zip>07645</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Lee Jones, PhD</last_name>
      <phone>646-888-8103</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>Memorial Sloan Kettering Commack</name>
      <address>
        <city>Commack</city>
        <state>New York</state>
        <zip>11725</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Lee Jones, PhD</last_name>
      <phone>646-888-8103</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>Memoral Sloan Kettering Westchester</name>
      <address>
        <city>Harrison</city>
        <state>New York</state>
        <zip>10604</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Lee Jones, PhD</last_name>
      <phone>646-888-8103</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>Memorial Sloan Kettering Cancer Center</name>
      <address>
        <city>New York</city>
        <state>New York</state>
        <zip>10065</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Lee Jones, PhD</last_name>
      <phone>646-888-8103</phone>
      <email>jonesl3@mskcc.org</email>
    </contact>
    <investigator>
      <last_name>Lee Jones, PhD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Memorial Sloan Kettering Nassau</name>
      <address>
        <city>Uniondale</city>
        <state>New York</state>
        <zip>11553</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Lee Jones, PhD</last_name>
      <phone>646-888-8103</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>LABORATORY CORPORATION OF AMERICA HOLDINGS (Data or Specimen Analysis Only)</name>
      <address>
        <city>Burlington</city>
        <state>North Carolina</state>
        <zip>27215</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Suzanne Carlisle</last_name>
      <phone>336-436-5760</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>Duke University Medical Center (Data or Specimen Analysis Only)</name>
      <address>
        <city>Durham</city>
        <state>North Carolina</state>
        <zip>27701</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Jason Locasale, PhD</last_name>
      <phone>919-684-9309</phone>
    </contact>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <link>
    <url>http://www.mskcc.org/mskcc/html/44.cfm</url>
    <description>Memorial Sloan Kettering Cancer Center</description>
  </link>
  <verification_date>May 2021</verification_date>
  <study_first_submitted>June 20, 2019</study_first_submitted>
  <study_first_submitted_qc>June 21, 2019</study_first_submitted_qc>
  <study_first_posted type="Actual">June 24, 2019</study_first_posted>
  <last_update_submitted>May 26, 2021</last_update_submitted>
  <last_update_submitted_qc>May 26, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">May 27, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Aerobic Exercise</keyword>
  <keyword>19-126</keyword>
  <patient_data>
    <sharing_ipd>Yes</sharing_ipd>
    <ipd_description>Memorial Sloan Kettering Cancer Center supports the international committee of medical journal editors (ICMJE) and the ethical obligation of responsible sharing of data from clinical trials. The protocol summary, a statistical summary, and informed consent form will be made available on clinicaltrials.gov when required as a condition of Federal awards, other agreements supporting the research and/or as otherwise required. Requests for deidentified individual participant data can be made beginning 12 months after publication and for up to 36 months post publication. Deidentified individual participant data reported in the manuscript will be shared under the terms of a Data Use Agreement and may only be used for approved proposals. Requests may be made to: crdatashare@mskcc.org.</ipd_description>
    <ipd_info_type>Statistical Analysis Plan (SAP)</ipd_info_type>
    <ipd_info_type>Informed Consent Form (ICF)</ipd_info_type>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

